Vanderbilt team uses cancer cells to fight West Nile virus.

November 21, 2018

Researchers at Vanderbilt University Medical Center say they have used cancerous cells to mass produce a human antibody that can be used to “neutralize” West Nile virus, a mosquito-transferred illness that kills about 100 people in the U.S. each year. Their findings, revealed this week in a research paper published in the scientific journal Nature Microbiology, could lead to the first effective treatment for West Nile, according to a news release.

Nasal gene spray inspired by llama antibodies could prevent all types of flu

November 5, 2018

Four llama antibodies and a harmless virus: This outlandish recipe could be the basis of a nasal spray designed to foil infection from all strains of influenza. The spray, containing a virus engineered to make a protein derived from the llama antibodies, has passed its first animal test, protecting mice from every known flu strain that infects humans, a research team reports.  

Llamas may hold the key to a long-lasting flu jab

November 5, 2018

Llamas may hold the key to a long-lasting flu vaccine, research suggests.  Laboratory tests showed a protein produced by the fluffy animals, as well as camels, fought off the virus in mice.  Rodents were even protected against 60 strains of flu, which cause fever, headache and fatigue in humans, for more than nine months.  Currently, flu jabs protect against a maximum of four strains - meaning people can still be struck down by strains that were not predicted to be active.  The Belgian study has even raised hopes of a flu nasal spray, after the mice were equally protected when the vaccine w

Norovirus: Vanderbilt study takes step toward norovirus vaccine, medicinal treatment

September 10, 2018

Norovirus earned its name as the "perfect pathogen"because it spreads faster and farther than most viruses, infecting 20 million people in the United States every year and killing 200,000 worldwide. Although the virus - the leading cause of gastrointestinal illness - survives typical disinfectants and is constantly changing, researchers at Vanderbilt University have taken a step toward developing a vaccine and toward improving diagnosis and treatment.

Crowe Lab Team finds potent antibodies against three Ebola viruses

August 1, 2018

Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. Reporting July 17 in the journal Immunity, they describe the isolation of two potent monoclonal antibodies from human survivors of Ebola virus disease that, in cell culture studies, efficiently neutralized the Zaire, Sudan and Bundibugyo ebolaviruses.

Anti-bodies that fight Ebola viruses are now a reality

August 1, 2018

Finally, anti-bodies to three major Ebola viruses have now been developed. Researchers at Vanderbilt University Medical Center are a step closer to developing a broadly effective antibody treatment against these viruses that cause the lethal disease in humans. Researchers found that the isolation of two potent monoclonal antibodies from human survivors of Ebola virus disease in cell culture studies efficiently neutralized the Zaire, Sudan and Bundibugyo Ebola viruses.

Ebola Antibodies Show Protection Potential in Animal Studies

July 23, 2018

Two types of antibodies from the blood of Ebola survivors protected animals against strains of the virus that cause deadly infections in people, researchers report. It may be possible to use these antibodies to create a treatment for Ebola, the researchers said.

Crowe Lab Wins Best Academic Research Award

April 10, 2018

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week. The congress is an annual meeting of vaccine professionals from industry, academia and nonprofit organizations. The awards are given to recognize outstanding achievements by companies, research teams and individuals in the vaccine industry.